A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...
PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
About half of men with medium-risk prostate cancer have just one tumour, occupying only 5 to 10 per cent of the prostate, yet ...
EXTENDED pelvic lymph node dissection (PLND) during radical prostatectomy significantly reduces the risk of metastasis in ...
American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...
High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.
SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback